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Addictive drugs induce a dopamine signal that con-
tributes to the initiation of addiction, and the dopa-
mine signal influences drug-associated memories
that perpetuate drug use. The addiction process
shares many commonalities with the synaptic plas-
ticitymechanisms normally attributed to learning and
memory. Environmental stimuli repeatedly linked to
addictive drugs become learned associations, and
those stimuli come to elicit memories or sensations
that motivate continued drug use. Applying in vivo
recording techniques to freely moving mice, we
show that physiologically relevant concentrations
of the addictive drug nicotine directly cause in vivo
hippocampal synaptic potentiation of the kind that
underlies learning and memory. The drug-induced
long-term synaptic plasticity required a local hippo-
campal dopamine signal. Disrupting general dopa-
mine signaling prevented the nicotine-induced syn-
aptic plasticity and conditioned place preference.
These results suggest that dopaminergic signaling
serves as a functional label of salient events by en-
abling and scaling synaptic plasticity that underlies
drug-induced associative memory.
INTRODUCTION
Dopamine (DA) signaling has a vital role during addiction. When
DA signaling is prevented, the reinforcing effects of drugs
decrease, as indicated by prevention or attenuation of self-
administration and place preference (Caine et al., 2007; Corrigall,
1999; Izzo et al., 2001; Stolerman and Shoaib, 1991). DA concen-
trations are not a direct indication of reward. Rather, DA likely
participates in the ongoing associative learning of adaptive
behaviors as an animal continually updates a construct of envi-
ronmental saliency. That viewpoint is consistent with evidence
indicating that addictive drugs act upon synaptic plasticity
mechanisms that normally underlie learning and memory (Dani
and Harris, 2005; Hyman et al., 2006; Jay, 2003; Jones and
Bonci, 2005; Kauer, 2004; Kelley, 2004; Ungless et al., 2004;
Winder et al., 2002).
The hippocampus, a key center of learning and memory,
receives dopaminergic afferents from the ventral tegmentalareas of the midbrain. Dopamine release in the hippocampus
enhances long-term potentiation (LTP) and learning, which
establishes a functional link between memory systems and
reward centers (Lisman and Grace, 2005). Evidence also indi-
cates that the hippocampus has an important role in the devel-
opment of drug addiction. For example, transgenic mice with
diminished hippocampal synaptic plasticity and deficits in
long-term memory are no longer able to develop drug-induced
place preference because the place of drug taking is hypothe-
sized not to be associated with the drug-induced reward
(Biala et al., 2005). One of the most important pathways for the
formation of associative memory is the perforant path, which
originates in the entorhinal cortex and relays convergent infor-
mation from the neocortex to the hippocampus (Deadwyler
et al., 1979; Lavenex and Amaral, 2000). In particular, we
focused on the medial perforant path because it specifically
carries place and spatial information (Hargreaves et al., 2005)
that is important for drug associated memory. The accumulated
evidence also supports that synaptic plasticity along this
pathway is a substrate of memory (Lynch, 2004; Martinez and
Derrick, 1996; McHugh et al., 2007; Rumpel et al., 2005).
There have been behavioral and in vitro advances showing
that nicotine can influence the induction of synaptic potentiation
(Davis et al., 2007; Ji et al., 2001; Matsuyama et al., 2000;
Nashmi et al., 2007). The in vivo experiments, however, used
deep urethane anesthesia that has been shown to alter the func-
tion of ligand-gated channels (Hara and Harris, 2002), and used
doses of nicotine that would cause seizures in awakemice (Fran-
ceschini et al., 2002; Miner and Collins, 1989). There has been
little or no research in freely moving animals that monitors the
ongoing induction of in vivo synaptic plasticity by a biologically
relevant dose of an addictive drug. Here we show that the addic-
tive drug, nicotine, dose-dependently induces long-term syn-
aptic potentiation of the kind that supports learning andmemory.
More importantly, the induction of the synaptic plasticity requires
a local DA signal within the hippocampus, consistent with the
view that DA enables memory for particular events (Schultz
et al., 1997). The results also suggest that the magnitude of the
DA signal influences the strength of the synaptic plasticity.
RESULTS
Nicotine-Induced Long-Term In Vivo Synaptic Plasticity
Field potentials evoked by stimulation of the medial perforant
path (Figure 1A) were recorded in the hilar region of the hippo-
campal dentate gyrus (Figure 1B) from freely moving C57BL/6Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc. 673
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Dopamine Enables Drug-Induced Synaptic Plasticitymice (Davis et al., 1997) (Figure 1C). We focused on the medial
perforant path because it relays convergent information from
the neocortex that is rich in contextual, place, and spatial content
(Hargreaves et al., 2005), and evidence indicates that such infor-
mation is associated with the drug experience (Biala et al., 2005;
Kilts et al., 2001). Field recordings were made from the hilus to
follow the field excitatory postsynaptic potential (fEPSP) and
the population (pop) spike that is produced when a population
of granule cells fire action potentials together. Synaptic trans-
mission was quantified by measuring the pop spike amplitude
(PS, angled arrow inset, Figure 1D) because the fEPSP is often
obscured by an increase in the pop spike that occurs after syn-
aptic potentiation induction in awake animals.
Two weeks after surgical implantation of the electrodes and
habituation to the recording situation, mice were treated with
three 4-day counterbalanced sessions of systemic intraperito-
neal injection (i.p.) of saline, 0.1, 0.5, or 1.0 mg/kg nicotine, re-
spectively. Neither saline nor 0.1 mg/kg nicotine affected trans-
mission, but 0.5 and 1.0 mg/kg nicotine induced long-term
synaptic potentiation (Figure 1D, red data squares for 1.0 mg/
kg, Figure S1 [available online] for 0.5 mg/kg). Systemic admin-
istration of nicotine induced synaptic potentiation of the fol-
lowing amplitude measured 3 hr after administration: 124.1% ±
6.4%, n = 3, p < 0.05 for 0.5 mg/kg and 159% ± 10%, n = 12,
p < 0.05 for 1.0 mg/kg (paired t test). Further tests indicated
that the nicotine-induced synaptic enhancement lasted for
more than 5 hr: 150.2% ± 9.6% of baseline for 1.0 mg/kg,
n = 3, p < 0.05 (paired t test, data not shown). Because the known
half-life of nicotine in mice is only 5–8 min (Petersen et al., 1984),
the synaptic potentiation is not due to the continued presence of
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Figure 1. Nicotine-Induced Synaptic Potentiation in the
Dentate Gyrus (DG) of Freely Moving Mice
(A) Placement of the concentric bipolar stimulating electrodes (double
red lines) into the medial perforant path.
(B) Placement of the recording electrode (red line) into the ipsilateral
hilus of the dentate gyrus.
(C) Photograph of a freely moving mouse during a recording session.
(D) Nicotine-induced potentiation of the perforant path recorded in the
DG. The time course of each procedure is across 4 days, from the day
before (1d) until 2 days after (2d) the nicotine administration. A 30min
baseline was obtained on 1d and confirmed to be stable for 30 min
on day 0 (0d). Saline (open circles, n = 8), 0.1 mg/kg nicotine (blue
circles, n = 7), or 1.0 mg/kg nicotine (red squares, n = 12) was injected
(i.p.) at 30 min on 0d (downward arrow). The population spike (PS)
amplitudes are plotted above to indicate potentiation of synaptic
transmission compared to the baselines (gray traces). Two-way anal-
ysis of variance (ANOVA) with repeated measures on day 0 showed
significant effects of groups (F2,24 = 20.36, p < 0.001) and group 3
time interactions (F82,984 = 2.96, p < 0.001). The PS amplitude
increased significantly over baseline and stayed potentiated for at
least 3 hr after 1.0 mg/kg nicotine on 0d (F41,451 = 7.91, p < 0.001).
The return to baseline is shown for 30 min on 1d and 2d. In this and
all subsequent figures, standard error bars are used.
nicotine; rather, the nicotine-induced synaptic potentia-
tion outlasts the presence of nicotine.
To test whether the nicotine-induced potentiation re-
sulted from an increase in the number of contributing
afferent axons, we measured the presynaptic fiber volley
during the nicotine-induced potentiation by moving the re-
cording electrode from the hilus to a position closer to the den-
dritic synaptic innervation. We found that the incoming afferent
excitation (i.e., the presynaptic fiber volley) was the same before
and after nicotine-induced potentiation of the pop spike (see
Figure S2): 102.6% ± 4.1%, n = 5, p > 0.05 (paired t test).
Thus, nicotine-induced synaptic potentiation of the perforant-
dentate pathway does not result from increased afferent fibers.
This result suggests that the potentiation resides beyond the
incoming action potential and likely postsynaptically as ex-
pected for LTP.
Next, we verified that nicotine acted via nicotinic acetylcho-
line receptors (nAChRs) to induce the synaptic potentiation. The
nonselective neuronal nAChR inhibitor, mecamylamine (2.0 mg/
kg, i.p.), was used (Gould and Wehner, 1999). We first showed
that injections of mecamylamine alone, at the concentration
(2.0 mg/kg, i.p.) we used, did not significantly alter baseline
synaptic transmission (Figure 2A). Saline injections (i.p.) pre-
ceding the nicotine administration still showed synaptic potenti-
ation (Figure 2B, gray data circles), but mecamylamine injection
(2.0mg/kg, i.p.) preceding the nicotine administration completely
prevented synaptic potentiation (Figure 2B, black data circles):
95.8% ± 11.4% of baseline, n = 5, p > 0.05 (paired t test).
Because the nicotine administrations are systemic, nicotine
could be influencing hippocampal plasticity by acting at sites
outside of the hippocampus. To determine whether nicotine is
acting locally only within the hippocampal dentate gyrus, nico-
tine was ipsilaterally microinfused into the dentate gyrus 300–
500 mmdorsal to the recording site (Figure 3A). Initially wemicro-
infused nicotine (0.008 mg, 0.5 ml/min over 2 min) to achieve674 Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc.
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Figure 2. Nicotinic Receptor Antagonist Mecamyl-
amine Inhibits Nicotine-Induced Potentiation
(A) Mecamylamine (2.0 mg/kg, i.p., n = 3) alone did not signif-
icantly alter evoked synaptic transmission from the perforant
path, as indicated by the stable amplitude of the population
spike (F44,88 = 0.61, p > 0.05).
(B) Mecamylamine (2.0 mg/kg, i.p., black circles, n = 5) admin-
istered 15 min prior to nicotine inhibited the nicotine-induced
synaptic potentiation when compared with saline injected 15
min before nicotine (gray circles, n = 3). ANOVA showed signif-
icant effects of groups (F1,6 = 35.28, p < 0.005) and groups 3
time (F44,264 = 2.76, p < 0.001).a concentration comparable to that attainedwith systemic i.p. in-
jection of 1mg/kg (as in Figure 1). When either nicotine (0.008 mg)
or saline, as a control, was slowly microinfused, there was no
significantchange insynaptic transmission (Figure3B). Ina recent
report, it was found that a much higher dose of nicotine (0.35 mg),
infused into the dorsal hippocampus, altered contextual fear
conditioning in mice (Davis et al., 2007). Therefore, we microin-
fused this higher dose into the dentate, but again there was no
significant change in synaptic transmission (Figure 3C). Although
these negative results are not conclusive, they suggest that nico-
tine has actions that extend beyond the hippocampal dentate
gyrus during the induction of the in vivo synaptic potentiation.
Nicotine-Induced Synaptic Potentiation Requires
a Hippocampal Dopamine Signal Arriving
from the Midbrain
An important feature of nicotine’s addictive potential arises from
nicotine-evoked firing of midbrain DA neurons, which produces
a potent DA signal (Nestler, 2004; Nisell et al., 1994; Pontieri
et al., 1996; Zhang et al., 2009). To determine whether the DA
signal induced by systemic injection of nicotine contributed tothe nicotine-induced synaptic potentiation, we systemically in-
hibited D1 and D5 (D1-type) DA receptors using SCH23390
(Ushijima et al., 1995) because D1-type receptors are expressed
in the hippocampus (Huang et al., 1992). Injections of SCH23390
(0.2 mg/kg, i.p.) alone did not significantly alter synaptic trans-
mission (Figure 4A). Systemic injection of SCH23390 (0.2 mg/kg,
i.p.) preceding the nicotine (1 mg/kg) administration, however,
completely prevented nicotine-induced synaptic potentiation
(Figure 4B, black data circles): 107.5% ± 11.1% of baseline, n =
7, p > 0.05. In control experiments where saline (i.p.) preceded
the nicotine administration, nicotine induced a significant poten-
tiation over the baseline (Figure 4B, gray data circles): 150.0% ±
7.7% of baseline, n = 8, p < 0.001.
To determine whether the D1-type receptor antagonism was
acting indirectly via distant targets or was acting locally within
the hippocampal dentate gyrus, SCH23390 was ipsilaterally
microinfused into the dentate gyrus (Figure 4E, black circles)
300–500 mm dorsal to the recording site (Figure 4E, gray trian-
gles). When either SCH23390 (1.0 mg) or saline, as a control,
was slowly microinfused alone into the dentate gyrus using an
infusion pump (0.5 ml/min over 2 min), there was no significantP
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Figure 3. Local Microinfusion of Nicotine into the Den-
tate Gyrus Does Not Induce Synaptic Plasticity of the
Perforant Path
(A) Four different schematic representations of the rostral-
caudal planes depict all five of the sites where nicotine wasmi-
croinfused (black circles) and the field potential was recorded
(gray triangles). The numbers represent the coordinate poste-
rior from bregma.
(B) Nicotine at the infusion dose (0.008 mg, n = 4) comparable
with systemic injection did not significantly alter evoked
synaptic transmission from the perforant path, as indicated
by the stable amplitude of the population spike (F41,123 =
0.45, p > 0.05).
(C) At an increased nicotine dose (0.35 mg, n = 5), local micro-
infusion still did not change the synaptic transmission of the
perforant path (F41,164 = 0.62, p > 0.05).Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc. 675
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Dopamine Enables Drug-Induced Synaptic Plasticitychange in synaptic transmission (Figure 4C). Microinfusion of
SCH23390 (1.0 mg, 0.5 ml/min over 2 min) into the dentate gyrus
preceding the nicotine administration, however, completely pre-
vented nicotine-induced synaptic potentiation (Figure 4D, black
data circles): 93.2% ± 16.6% of baseline, n = 6, p > 0.05. In
paired control experiments where saline microinfusion preceded
the nicotine administration, nicotine induced a significant poten-
tiation over the baseline (Figure 4D, gray data circles): 141.8% ±
8.7%, n = 6, p < 0.001. The results indicate that D1-type recep-
tors act locally within the hippocampal dentate gyrus to enable
nicotine-induced long-term synaptic potentiation.
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Figure 4. Systemic or Local Hippocampal Microinfu-
sion of Dopamine D1-type Receptor Antagonist
SCH23390 Inhibits Nicotine-Induced Potentiation
(A) Systemic administration of SCH23390 (0.2 mg/kg, i.p.,
n = 3) alone did not significantly alter evoked transmission of
the perforant path (F41,82 = 1.06, p > 0.05).
(B) SCH23390 (0.2 mg/kg, i.p., black circles, n = 7) adminis-
tered 30 min prior to nicotine inhibited the synaptic potentia-
tion when compared to saline injected 30 min before nicotine
(gray circles, n = 8). ANOVA showed significant effects of
groups (F1,13 = 10.09, p < 0.01) and groups 3 time (F44,572 =
2.19, p < 0.001).
(C) Microinfusion of SCH23390 (1.0 mg, n = 5) directly into the
DG had no effect on the basic synaptic transmission in the per-
forant path (F41,164 = 0.38, p > 0.05).
(D) Microinfusion of SCH23390 (1.0 mg, black circles, n = 6)
directly into the DG 15 min before nicotine injection inhibited
nicotine-induced potentiation. When saline (1.0 ml) was micro-
infused before nicotine (gray circles, n = 6), nicotine-induced
potentiation was observed. ANOVA showed the significant
differences (groups: F1,10 = 6.62, p < 0.05; groups 3 time:
F44,440 = 1.48, p < 0.05).
(E) Four different schematic representations of the rostral-
caudal planes depict all six of the sites where SCH23390
was microinfused (black circles) and the field potential was re-
corded (gray triangles). The numbers represent the coordinate
posterior from bregma.
D2-type receptors regulate the firing of DA neu-
rons by autoinhibition at theirmidbrain source (Rob-
inson et al., 2004; Zhang et al., 2009). Therefore, we
used a D2-type agonist, quinpirole (0.2 mg/kg, i.p.),
to inhibit DA neuron firing and, consequently, to
decease the outgoing DA signal (Job et al., 2006;
Robinson et al., 2004). Injections of quinpirole (0.2 mg/kg, i.p.)
alone did not significantly alter perforant-path synaptic trans-
mission (Figure 5A). Injection of quinpirole (0.2 mg/kg, i.p.)
preceding the nicotine administration, however, prevented nico-
tine-induced synaptic potentiation (Figure 5B, black data circles):
119.9%±9.5%of baseline, n =5, p>0.05. In control experiments
where saline (i.p.) preceded the nicotine administration, nicotine
induced a significant potentiation over the baseline (Figure 5B,
gray data circles): 157.7% ± 8.1%, n = 11, p < 0.001.
To verify the DA signal was required and not just inhibition of
D2-type receptors, we ipsilaterally microinfused tetrodotoxin
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Figure 5. Systemic Dopamine D2-type Receptor
Agonist Quinpirole Inhibits Nicotine-Induced Potenti-
ation
(A) Systemic administration of the D2-type receptor agonist
quinpirole (0.2 mg/kg, i.p., n = 4) alone did not significantly
alter evoked transmission of the perforant path (F42,126 =
0.93, p > 0.05).
(B) Quinpirole (0.2 mg/kg, i.p., black circles, n = 5) adminis-
tered 30 min prior to nicotine (1.0 mg/kg, i.p.) inhibited the
nicotine-induced potentiation when compared with saline in-
jected 30 min before nicotine (gray circles, n = 11). ANOVA
showed the significant differences (groups: F1,14 = 9.14, p <
0.01; groups 3 time: F43,602 = 2.06, p < 0.001).676 Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc.
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Figure 6. Local Microinfusion of TTX Inactivates
Midbrain Neurons and Abolishes Nicotine-Induced
Potentiation
(A) Three different schematic representations of the
rostral-caudal planes depict all five of the sites where
TTX was microinfused (black circles) into the midbrain
ventral tegmental area (VTA, arrow). The numbers repre-
sent the coordinate posterior from bregma, and the labels
are parvicellular red nucleus (RPC), magnocellular red
nucleus, (RMC), substantia nigra reticulata (SNR).
(B) Microinfusion of TTX (2.0 mM, 0.5 ml, n = 3) into the VTA
had no effect on the basic synaptic transmission of the
perforant path (F41,82 = 1.07, p > 0.05).
(C) Microinfusion of TTX (2.0 mM, 0.5 ml, black cycles, n = 5)
into the VTA 20 min before nicotine injection inhibited
nicotine-induced potentiation.When saline (0.5 ml) wasmi-
croinfused before nicotine (gray circles, n = 5), nicotine-
induced potentiation was observed. ANOVA showed the
significant differences (groups: F1,8 = 11.02, p < 0.05;
groups x time: F45,360 = 2.50, p < 0.01).(TTX) into the midbrain DA area to inhibit sodium channels
and, consequently, inhibit action potentials from the DA neurons.
When either TTX (2.0 mM in 0.5 ml/min over 1 min) or saline, as
a control, was slowly microinfused alone into the midbrain DA
area (Figure 6A), there was no significant change in hippocampal
synaptic transmission (Figure 6B). Microinfusion of TTX (0.5 ml/
min over 1 min) (Legault et al., 2000) preceding the nicotine ad-
ministration, however, completely prevented nicotine-induced
synaptic potentiation (Figure 6C, black data circles): 96.8% ±
6.7% of baseline, n = 5, p > 0.05. In paired control experiments
where salinemicroinfusion preceded the nicotine administration,
nicotine induced a significant potentiation over the baseline (Fig-
ure 6C, gray data circles): 149.1% ± 12.6%, n = 5, p < 0.05. The
results indicate that a DA signal arising from the midbrain is
required to enable nicotine-induced long-term synaptic potenti-
ation within the hippocampal dentate gyrus.
Rather than inhibiting DA signaling, the D2-type receptor
antagonist eticlopride increases the firing rates of DA neurons
at their midbrain source (Brady and O’Donnell, 2004; Robinson
et al., 2004; Zhang et al., 2009). Injections of eticlopride(0.5 mg/kg, i.p.) alone did not significantly alter perforant-
path synaptic transmission (Figure 7A). Injection of eticlopride
(0.5 mg/kg, i.p.) preceding the nicotine administration, however,
statistically enhanced nicotine-induced synaptic potentiation
(Figure 7B, black data circles): 205.4% ± 17.5% of baseline,
n = 6, p < 0.001. In control experiments where saline (i.p.)
preceded the nicotine administration, nicotine induced a signifi-
cant (but statistically smaller) potentiation over the baseline
(Figure 7B, gray data circles): 157.7% ± 8.0%, n = 11, p <
0.001. The results suggest that the strength of the nicotine-
induced synaptic potentiation is influenced by the magnitude
of the DA signal.
Nicotine-Induced Conditioned Placed Preference
Requires Dopamine D1-type Signaling
The results to this point indicate that nicotine induces synaptic
plasticity that requires D1-type receptor activity. To examine
whether the electrophysiological results are consistent with
memory-based behavioral outcomes, we tested nicotine-
induced conditioned place preference (CPP). Others have0 60 120 180 240
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Figure 7. Systemic Dopamine D2-type Receptor
Antagonist Eticlopride Increases Nicotine-Induced
Potentiation
(A) Systemic administration of the D2-type receptor antag-
onist eticlopride (0.5 mg/kg, i.p., n = 3) alone did not signif-
icantly alter evoked transmission from the perforant path
(F47,47 = 0.62, p > 0.05).
(B) Eticlopride (0.5 mg/kg, i.p., black circles, n = 6) admin-
istered 30 min prior to nicotine (1.0 mg/kg, i.p.) enhanced
nicotine-induced potentiation when compared with
saline injected 30 min before nicotine (gray circles, n = 11)
(group 3 time: F43,645 = 1.91, p < 0.001).Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc. 677
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Dopamine Enables Drug-Induced Synaptic Plasticityshown that the hippocampus participates in CPP (Meyers et al.,
2003, 2006). In addition, nicotine-induced CPP requires nAChR
activity, and there is an inverted U-shaped dose response with
0.5 mg/kg of nicotine causing the strongest CPP (Walters
et al., 2006). We found that concentration of nicotine (0.5 mg/
kg) also induces in vivo synaptic plasticity (Figure S2).
Using procedures adapted from published methods (Walters
et al., 2006), we found significant CPP (Figure 8) in response to
nicotine (Nic, 0.5 mg/kg, i.p., p < 0.05, n = 10) compared with
saline (Sal, n = 10). Then, we examined whether dopamine D1-
type receptor activity, which is required for nicotine-induced
synaptic plasticity, is also required forCPP. Although saline injec-
tion before conditioning still resulted in nicotine-induced CPP
(Figure 8, Sal + Nic, n = 12), CPP was not induced when the
D1-type inhibitor SCH23390 (0.2 mg/kg, i.p.) was administered
20min before conditioning (Figure 8, SCH+Nic, n = 12, p < 0.05).
DISCUSSION
Nicotine-Induced In Vivo Synaptic Plasticity, Condition
Place Preference, and Implications
In this study, in vivo synaptic transmission was directly
measured in freely moving mice, and an addictive drug, nicotine,
dose-dependently induced synaptic plasticity of the kind that
underlies learning and memory (Kauer, 2004; Kelley, 2004; Whit-
lock et al., 2006; Winder et al., 2002). Although saline or low
doses of nicotine did not alter synaptic transmission, two higher
and behaviorally relevant nicotine doses (Grabus et al., 2006)
caused long-lasting synaptic potentiation that was stable for at
least 5 hr. Biologically relevant nicotine doses in mice are larger
than in rats because nicotine has a very short half-life of 5 to 8
min in mice (Petersen et al., 1984). The rapid turnover means
that the nicotine concentration in the mice fell to less than 1%
in 1 hr. Therefore, the nicotine-induced synaptic potentiation
outlasted the presence of nicotine by hours.
More importantly, pharmacological manipulations indicated
that the drug-induced synaptic plasticity required a DA signal
broadcast from themidbrain that acted locally within the dentate
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Figure 8. Dopamine D1-type Receptor Antagonist SCH23390
Inhibits Nicotine-Induced Conditioned Place Preference
Mice treated with 0.5 mg/kg nicotine (Nic, n = 10) exhibited significant CPP
compared with saline-treated controls (Sal, n = 10, *p < 0.05). Saline injection
before nicotine did not alter the CPP score (Sal + Nic, n = 12). In contrast,
SCH23390 (0.2 mg/kg, i.p.) prior to nicotine abolished nicotine-induced CPP
(SCH + Nic, n = 12, *p < 0.05).678 Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc.gyrus of the hippocampus. Systemic or local inhibition of dopa-
mine D1-type receptors within the dentate gyrus prevented the
nicotine-induced potentiation. The impact of D2-type receptor
manipulations is different. D2-type agonists activate negative
feedback via D2 autoreceptors and decrease the DA signal to
the hippocampus by suppressing DA neuron firing (Robinson
et al., 2004; Zhang et al., 2009). Likewise, active D2 autorecep-
tors on DA terminals inhibit DA release in the hippocampus,
which also decreases the DA signal. Therefore, systemic activa-
tion of D2-type receptors, which inhibits DA neuron firing and DA
release, prevented nicotine-induced potentiation. This explana-
tion was supported because inhibiting DA neuron action poten-
tials by microinfusion of TTX into the midbrain also prevented
nicotine-induced plasticity. However, systemic inhibition of D2
receptors, which boosts DA neuron firing (Robinson et al.,
2004; Zhang et al., 2009), enhanced the amplitude of nicotine-
induced potentiation. Overall, the results suggest that DA en-
ables, at least, this form of synaptic plasticity, and the strength
of the DA signalmodulates the amplitude of the induced synaptic
potentiation.
The nicotine-induced CPP results help to link the synaptic
measurements to a memory-based behavior. It has previously
been shown that nicotine displays an inverted U-shaped dose
response (Walters et al., 2006). Consistent with our nicotine-
induced synaptic potentiation, nicotine induces CPP at 0.5 mg/
kg but not at 0.1 mg/kg, which is likely too low a dose for either
effect. Nicotine at 1 mg/kg induces synaptic potential, but it did
not induce significant CPP (Walters et al., 2006). That result is not
too surprising. At this higher concentration, nicotine is a slight
sedative in mice, causing them to become relatively immobile.
In fact, this property lowers the mouse core body temperature
at 1 mg/kg nicotine (Marks et al., 1986), which likely causes
the delayed onset of synaptic potentiation seen at 1 mg/kg nico-
tine (Figure 1D) but not seen at 0.5 mg/kg, which does not cause
sedation (Figure S1). Furthermore, at 1 mg/kg nicotine is ap-
proaching doses that cause adverse autonomic effects. There-
fore, the synaptic plasticity results lead us to hypothesize that
the mice are learning in association with the 1 mg/kg nicotine
injection, but they might be learning place avoidance nearly as
often as place preference. Coupled with the complication of
nicotine sedation, 1 mg/kg is a dose that is beyond the optimum
for CPP.
It has been shown that drug-induced CPP requires the dorsal
hippocampus, where we make our measurements. Excitotoxic
lesion or inactivation of the dorsal hippocampus by muscimol
prevented CPP (Meyers et al., 2003, 2006). In a very recent
study, the role of the dorsal hippocampus in CPP also was
confirmed in C57 mice that we use (Tropea et al., 2008). There-
fore, the dorsal hippocampus contributes to CPP. Because the
DA receptor antagonist was administered systemically in our
CPP experiment, we can only correlate the nicotine-induced
synaptic potentiation, the DA signaling, and the CPP. A study
has shown, however, that dorsal hippocampal DA receptors
play a role in morphine reward (Rezayof et al., 2003). Intrahippo-
campal injection of D1-type receptor agonist SKF38393 signifi-
cantly potentiated morphine-induced CPP, and this effect was
reversed by D1-type receptor antagonist SCH23390 (Rezayof
et al., 2003). Those results support a mechanistic connection
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observed. Overall, our in vivo and behavioral results provide
a link between an addictive drug and DA’s influence over the
memory circuits that create associations to the act of drug use
(Dani and Montague, 2007; Kauer, 2004; Kelley, 2004). The
medial perforant path carries contextual and spacial information
from the cortex to the hippocampus (Deadwyler et al., 1979;
Hjorth-Simonsen and Jeune, 1972; Lavenex and Amaral, 2000).
The hippocampus receives cholinergic innervation arisingmainly
from the medial septum and diagonal band (Woolf, 1991) and
densely expresses nicotinic acetylcholine receptors (Dani and
Bertrand, 2007). In addition, the hippocampus receives dopami-
nergic innervation from the ventral tegmental area, and nicotine
increases the firing rates of thosemidbrain DA neurons (Grenhoff
et al., 1986; Mameli-Engvall et al., 2006; Zhang et al., 2009). The
results from this study indicate that the DA signal acts to enable
synaptic potentiation by nicotine in the dentate gyrus. The results
suggest that as information continually flows through the perfo-
rant path to the hippocampus, the DA signal provides a time
stamp that labels particular events for storage as memories
(Wise, 2004). In one view, the DA signal arises during unpre-
dicted events in the environment that require learning to update
the repertoire of adaptive behaviors (Schultz et al., 1997). We
speculate that normally important events in the environment
will produce the convergence of perforant path activity and
a DA signal to produce synaptic potentiation. In our example,
the nicotine administration produced the convergence of perfo-
rant path synaptic activity and the DA signal.
Drug-Associated Memories Contribute to Continued
Drug Use
This study was based on the hypothesis that addictive drugs
produce synaptic plasticity that underlies drug-linked associa-
tive memory (Kauer, 2004; Kelley, 2004; Winder et al., 2002).
This hypothesis is consistent with the emerging view that memo-
ries associated with addictive behaviors become internal moti-
vational drives to continue drug use (Bonson et al., 2002; Dani
and Montague, 2007; Everitt et al., 2001; Kenny and Markou,
2005; Kilts et al., 2001). That is, environmental cues previously
associated with drug use elicit internal sensation-based memo-
ries thatmotivate the desire for the drug,making long-term absti-
nence difficult.
Normally, neural systems operating beneath our conscious-
ness enable us to associate environmental situations with be-
havioral sequences that produce success (Everitt et al., 2001;
Packard and Knowlton, 2002; Schultz et al., 1997). Eventually,
those same environmental situations cue internal states (i.e.,
feelings or sensations) that motivate the successful behaviors.
In that way, we continually learn how to exploit our environments
successfully. Dopamine signals might serve as a label during this
learning process, indicating when the environment presented
unexpected events that needed to be updated in our mnemonic
map of environmental saliency (Schultz, 2001; Schultz et al.,
1997; Wise, 2004).
Addictive drugs usurp these normally adaptive systems, which
include the dopaminergic system originating in the ventral teg-
mental area of the midbrain. When an addictive drug is used,
there are associated behaviors and environmental events oblig-atorily linked to the usage. Addictive drug use can be considered
a learned (conditioned) behavior reinforced by the drug. Those
events associated with the drug also are subject to conditioning.
A recent fMRI study of addicted smokers showed that cues
related to smoking elicit neural activity in regions linked to atten-
tion, memory, emotion, and motivation (Smolka et al., 2006). In
rats, presentation of nicotine-associated cues reinstated previ-
ously extinguished nicotine-seeking behavior, providing evi-
dence that links nicotine-associated cues to relapse (Paterson
et al., 2005).
Based on the background of information, the results provide
interesting suggestions. As information continuously passes
through the hippocampus, most information is not stored but
particular salient events are labeled by a phasic DA signal that
enables synaptic plasticity and, subsequently, memory. That is,
an animal’s construct or internal memories of the environment
are updated when the DA signal labels the particular event as
important, new, and salient. In the case presented in this study,
those memories would be linked to the addictive drug. When
specific environmental events are present (e.g., the location of
drug use), they are capable of cuing drug-associated memories
or feelings that motivate continued drug use or relapse (Paterson
et al., 2005; Smolka et al., 2006).
EXPERIMENTAL PROCEDURES
Animal Care and Surgery
Adult male C57BL6/J mice (Jackson Laboratory), 3–4 months old, were used
in all the experiments. For electrophysiology, they were housed individually
with food and water ad libitum in a temperature-controlled room (23C ±
0.5C) with a 12 hr artificial light-dark cycle (light on at 9 p.m.). All experiments
took place during the dark phase of the cycle. The Institutional Animal Care
and Use Committee approved all procedures in accordance with federal
guidelines.
On day 0, mice were anesthetized with sodium pentobarbital (80mg/kg, i.p.,
supplemented with 15 mg/kg as necessary) and secured in stereotaxic appa-
ratus. A concentric bipolar stimulating electrode consisting of a tungsten wire
placed inside a stainless steel tube was placed at the medial part of the perfo-
rant path (0.2 mm posterior and 2.8–3.0 mm lateral of lambda, 1.0–1.3 mm
below the dura). The recording electrode (Teflon-coated tungsten wire, bare
diameter 50 mm) attached to a stainless steel guide tube (outer diameter
310 mm) was targeted ipsilaterally to the hilus of the dentate gyrus (DG) (1.8–
2.0 mm posterior, 1.4–1.6 mm lateral of bregma, 2.2–2.3 mm below the skull)
(Franklin and Paxinos, 1997). Final depths of the electrodes were determined
by electrophysiological guidance. A cortical silver ball, placed contralaterally,
served as a recording reference as well as ground. Surgical screws and dental
cement were used to anchor the electrodes, a unity gain preamplifier, and the
connecting device for chronic recordings. Mice were given at least 2 weeks to
recover.
Handling, Habituation, Stimulation, and Recording Procedures
From day 10 for a total of 5 days, each animal received 5min handling followed
by 0.3 ml saline (i.p.) in the home cage both in the morning and afternoon. Then
the mice were individually habituated to the recording chamber (Plexiglas
cylinder with bedding) and to the recording headstage system. Mice received
1 hr of habituation daily for 4 consecutive days starting from day 11. On the
days of habituation and testing, mice were slightly sedated with isoflurane
for 3–5 s to connect the implanted electrode assembly to the recording head-
stage (Tang et al., 2001). Monophasic square pulses (100 ms) were delivered to
the perforant path. Signals were amplified (3 100), filtered (bandpass 0.1 Hz to
5 kHz), digitized at 10 kHz, and stored on disk for off-line analysis.
On day 15, an input-output curve (I/O) was generated. Single test stimuli
were then delivered at 30 s intervals at an intensity (35–100 mA) that evokedNeuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc. 679
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ments examining evoked synaptic responses in the perforant path-dentate
pathway, there were two to three counterbalanced sessions for every indi-
vidual mouse: saline, 0.1 mg/kg, and 0.5 mg/kg or 1.0 mg/kg nicotine. Each
session went across 4 days. On day minus one (1d), the baseline amplitude
of the population spike was examined for stability for 30 min. On 0d, after 30
min of baseline recording, saline, 0.1 mg/kg, 0.5 mg/kg, or 1.0 mg/kg nicotine
was administered (i.p.) at a volume of 0.1 ml per 10 g body weight. The
responses were usually monitored for another 3 hr following the injection,
but in some cases the responses were monitored for 5 hr. The posttests
were repeated for 30 min on 1d and 2d. I/O curves were recorded systemati-
cally between two sessions to verify the stability and the recovery after the
treatment of each session.
Throughout the electrophysiological recording, the mouse’s behavior was
videomonitored, and the EEG derived from the dentate gyrus recording also
was displayed on an oscilloscope to ensure the absence of electrical after
discharges and to ensure the mouse was in a ‘‘still-alert’’ state (Doyere
et al., 2003).
Drug Administration and Histology
All the drugs were from Sigma (St. Louis, MO). For intraperitoneal injection,
()-nicotine hydrogen tartrate salt (calculated as the free base), mecamyl-
amine hydrochloride, R(+)-SCH-23390 hydrochloride, S()-eticlopride hydro-
chloride, and ()-quinpirole hydrochloride were dissolved in saline and
adjusted for 0.1 ml per 10 g body weight.
For intracranial microinfusion, solutions were adjusted to pH 7.4 with NaOH
and back filled into a 30 gage injector. Nicotine (0.008 or 0.35 mg) or the dopa-
mine D1 receptor antagonist SCH23390 or saline was injected slowly using an
infusion pump into the DG at 0.5 ml/min over either 1 or 2 min. Pilot tests with
lidocaine in anesthetized and freely moving mice verified that this procedure
worked well. To avoid the mechanical effect of the cannula insertion on the
electrophysiological recording, the injector tip was located 0.3–0.5 mm above
the recording sites in the DG. For VTA inactivation with TTX, a 24G guide
cannula was implanted (3.2 mm posterior and 0.5 mm lateral of bregma,
3.0 mm below the skull). The tip of the injector was 1.2 mm below the guide
tip. Saline or TTX (0.5 ml over 1 min) was infused into the VTA 20 min before
nicotine administration (i.p.). Following drug infusion, cannulas were left in
place for another minute to allow diffusion of the drug away from the cannula
tip. At the end of the microinfusion experiments, 4% methylene blue in phos-
phate-buffered saline (0.5 ml) was injected into the infusion site. Mice were later
killed with an overdose of isoflurane. An anodal current (30 mA, 10 s) was
passed through the tungsten wire for identification of the electrode place-
ments. Frozen 30 mm coronal sections were cut and stained with hematoxylin.
Behavioral Procedures
C57BL6/J mice (3.5–4 months old) were used for the CPP experiments. The
procedure for handling and habituation of needle injection was the same as
that used for the mice in physiological recordings. The procedures and appa-
ratus for the nicotine-induced CPP were adapted from published methods
(Walters et al., 2006).
Because most of our mice in the pilot test did not show initial bias to one of
two sides of the conditioning apparatus, an unbiased protocol consisting of
three phases was used. (1) Preconditioning was conduced on day 1. Each
mouse was placed separately into the apparatus for 15 min, with free access
to both compartments. The time spent in each compartment was recorded by
ANY-maze software (Stoelting Inc., Kiel, WI). (2) Conditioning took place on
days 2–4. In experiment 1, mice received saline or 0.5 mg/kg nicotine (i.p.)
and were immediately confined to the pairing compartment for 30 min in the
morning. Five hours later in the afternoon, animals were injected with the alter-
nate nicotine or saline and immediately confined to the opposite compartment
for 30 min. Saline control groups received saline on both sides of the appa-
ratus. This procedure was repeated on days 3 and 4. A counterbalanced
design was used between the two compartments, morning and afternoon
sessions and from day to day. In experiment 2, the conditioning protocol
was exactly the same as experiment 1 except for the pharmacological treat-
ment. For this experiment, mice first received saline or 0.2 mg/kg SCH23390
(i.p.) and stayed in their home cages. Twenty minutes later all the animals680 Neuron 63, 673–682, September 10, 2009 ª2009 Elsevier Inc.were given 0.5 mg/kg nicotine (i.p.) before being confined to one of the two
compartments. (3) Testing was done on day 5. The mice were able to freely
explore the full apparatus for 15 min and time spent on each side was re-
corded. Preference score was expressed in seconds and is calculated by sub-
tracting preconditioning day data from test day data.
Data Analysis
The amplitude of the population spike was measured for each evoked
response. The values from every ten consecutive recordings were averaged
and normalized for each animal as a percentage of the mean baseline values
obtained during the 30 min immediately before drug treatment. Data were ex-
pressed as mean and standard error of the mean and analyzed with two-way
repeated-measures analysis of variance. Post hoc tests for time3 group inter-
actions were first assessed with another repeated-measure analysis of vari-
ance for the time variable operating only on a single group. Significant time
effects were then explored with paired t tests by comparing the mean of all
baseline points with each postbaseline time bin. Group effects in the time 3
group interaction were assessed with one-way analyses of variance for each
time point. For experiments with more than two levels to the group variable
(e.g., Figure 1A) a SNK post hoc was used.
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be foundwith this article online
at http://www.neuron.org/supplemental/S0896-6273(09)00580-7.
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